Morphocell Technologies Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
44
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$50M
- Investors
-
3
Morphocell Technologies General Information
Description
Operator of a regenerative medicine company intended to advance treatments using stem cell-based therapies. The company's cell therapy functions as an allogeneic solution that does not necessitate immunosuppression and can be extracted without lasting effects once liver function is restored through minimally invasive procedures, enabling medical professionals with an effective option for acute and chronic liver failure.
Contact Information
Website
www.morphocell.comCorporate Office
- 275 Armand-Frappier Boulevard
- Laval, Quebec H7V 4A7
- Canada
Corporate Office
- 275 Armand-Frappier Boulevard
- Laval, Quebec H7V 4A7
- Canada
Morphocell Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Later Stage VC (Series A) | 01-Dec-2025 | $50M | Completed | Pre-Clinical Trials |
Morphocell Technologies Patents
Morphocell Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-7699644-B2 | Process for generating a hepatic lineage cell population from endodermal cells and cell compositions comprising same | Active | 25-May-2018 | ||
| JP-2024028866-A | Process for making cell populations of hepatic lineage from endodermal cells and cellular compositions comprising same | Active | 25-May-2018 | ||
| JP-2025148360-A | Process for making cell populations of hepatic lineage from endodermal cells, and cellular compositions comprising the same | Pending | 25-May-2018 | ||
| AU-2019273134-A1 | Process for making cell populations of the hepatic lineage from endodermal cells and cellular compositions comprising same | Active | 25-May-2018 | ||
| AU-2019273134-B2 | Process for making cell populations of the hepatic lineage from endodermal cells and cellular compositions comprising same | Active | 25-May-2018 | C12N5/0679 |
Morphocell Technologies Signals
Morphocell Technologies Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDP Venture Capital (Rome) | Venture Capital | Minority | ||
| Genson Capital | Venture Capital | Minority | ||
| Investissement Quebec | PE/Buyout | Minority |
Morphocell Technologies FAQs
-
When was Morphocell Technologies founded?
Morphocell Technologies was founded in 2018.
-
Where is Morphocell Technologies headquartered?
Morphocell Technologies is headquartered in Laval, Canada.
-
What is the size of Morphocell Technologies?
Morphocell Technologies has 44 total employees.
-
What industry is Morphocell Technologies in?
Morphocell Technologies’s primary industry is Drug Discovery.
-
Is Morphocell Technologies a private or public company?
Morphocell Technologies is a Private company.
-
What is Morphocell Technologies’s current revenue?
The current revenue for Morphocell Technologies is .
-
How much funding has Morphocell Technologies raised over time?
Morphocell Technologies has raised $50M.
-
Who are Morphocell Technologies’s investors?
CDP Venture Capital (Rome), Genson Capital, and Investissement Quebec have invested in Morphocell Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process